Viewing Study NCT07279935


Ignite Creation Date: 2025-12-24 @ 10:32 PM
Ignite Modification Date: 2025-12-25 @ 8:05 PM
Study NCT ID: NCT07279935
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-12-12
First Post: 2025-12-01
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.
Sponsor: AstraZeneca
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module